i-ImmunDx™ Platform and POCT Products

Seinda’s i-ImmunDx™ platform is built on extensive analysis of ophthalmic clinical samples, yielding rich disease biomarker data. Known for its high sensitivity and accuracy, it uses minimal sample volume and provides fast results. The system features a micro-capillary fluid collector, point-of-care diagnostics, and an advanced analyzer, targeting key biomarkers such as LTα3 (LTA), IgE, MMP-9, IL-6, and IL-8.

View Product Info

i-ImmunDx™ enhances clinical diagnostics, supports disease management, and advances scientific research into ocular conditions, contributing significantly to precision medicine.

i-ImmunDx™ Analyzer

Sensitive. Precise. Foolproof.The i-ImmunDx™ Analyzer is Seinda’s proprietary diagnostic platform engineered to deliver high-sensitivity, high-precision results for tear-based biomarker testing—quickly and reliably at the point of care.
Designed for use with all Seinda test cassettes, the analyzer ensures ease-of-use, built-in safety features, and robust quality control, making it a trusted companion in busy clinical environments.

  • High Sensitivity & Precision
    Detects low-concentration tear biomarkers with excellent reproducibility, supporting early and accurate diagnosis.
  • Foolproof Operation
    Each test cassette features a unique barcode that is automatically scanned by the analyzer—eliminating user error and ensuring the correct protocol is followed for each test type.
  • Built-in Safety & Quality Control
    The analyzer continuously monitors internal parameters and test validity, alerting the user to any issues. Test integrity is protected at every step.
  • Ease-of-Use
    Minimal training required. Load the cassette, insert the sample (1–2 µL), and receive results within 10–15 minutes. Compact and portable for point-of-care flexibility.
  • Test-Specific Calibration
    Barcode-linked protocols ensure each assay is run with precisely the right calibration curve and detection parameters—ensuring both standardization and accuracy.
  • Auto-Adaptation for New Tests
    No software updates required. Every new test cassette carries its own encoded protocol, enabling seamless compatibility with the existing analyzer.

Why i-ImmunDx™ is Different:
Unlike immuno detection lateral, i-ImmunDx™ combines the clinical-grade rigor of a lab instrument with the speed and convenience of a point-of-care tool—bridging innovation and practicality

Two Test Modes:

Standard Test: Test cassette is immediately inserted into Analyzer after sample is added, so the user can multi-task during sample reaction time (10-15 minutes)

Quick Test: Test cassette is inserted after the reaction time is complete, allowing multiple tests to be performed in a single time frame(results in seconds).

– High-capacity storage

– Saves results automatically, allowing stored data to be easily aexported onto computers or recovered in the event of power failure.

– Built-in thermal printer for printing test results in real time

– Barcode scanner for easy identification of test cassettes and results

  • Dimensions: 173 mm(W)x84mm(H)x210mm(D)
  • Weight: 1.5kg

To purchase or request more information, send us an email at sales@seindabio.com or send us a message.

Microfluidic Tear Collector

Precision Sampling, Painless Collection
Seinda’s Microfluidic Tear Collector is a proprietary, single-use device engineered for fast, comfortable, and contamination-free collection of tear fluid.
Optimized for compatibility with all Seinda biomarker tests, it ensures sample integrity and reproducibility—supporting high-quality diagnostics at the point of care.

• Minimally Invasive & Comfortable:
Designed to gently collect 1–2 µL of tear fluid without stimulating reflex tearing or causing irritation.
• Microfluidic Precision:
Channels tear fluid through a capillary-guided path, preserving analyte concentration and ensuring consistency across tests.
• Sample Integrity:
Avoids contact with skin or conjunctiva, reducing the risk of contamination and protecting the fidelity of sensitive biomarker readings.
• Single-Use & Sterile:
Individually packaged and disposable to maintain hygienic standards and eliminate cross-contamination.
• Integrated with i-ImmunDx™ Workflow:
Specifically designed to deliver optimal volume and sample quality for Seinda’s point-of-care assays—ensuring smooth, reliable testing every time.

Why It Matters:
Accurate diagnostics start with clean, consistent sample collection. Seinda’s Microfluidic Tear Collector bridges comfort and performance, enabling clinicians to gather high-quality tear samples in seconds—without discomfort, dilution, or compromise.

Material: plastic
Available in various sizes, with sterile and nonsterible options.

To purchase or request more information, send us an email at sales@seindabio.com or send us a message.

LTA-POC

Quantifying Immune Balance in Dry Eye Disease

The LTA-POC is a rapid, quantitative immunoassay developed to measure Lymphotoxin-α (LTA) levels in human tear samples.

Utilizing Seinda’s proprietary i-ImmunDx™ Analyzer, this test provides clinicians with precise insights into ocular surface immune homeostasis, facilitating accurate diagnosis and patient stratification in dry eye disease (DED).

Clinical Significance:

LTA plays a pivotal role in maintaining ocular immune tolerance by activating regulatory T cells (Tregs) through the TNFR2 pathway. Reduced LTA levels in tears have been associated with disrupted immune homeostasis, a key factor in the pathogenesis of DED. By quantifying LTA, the LTA-POC test aids in identifying patients with immune-mediated DED, supporting personalized treatment strategies and monitoring therapeutic efficacy.

Key Features:

  • Rapid Results: Delivers quantitative measurements within 10–15 minutes at the point of care.
  • High Sensitivity and Specificity: Detects LTA concentrations as low as 1 picogram, ensuring reliable assessment of immune status.
  • Minimal Sample Requirement: Requires only 1–2 µL of tear fluid, enhancing patient comfort and ease of collection.
  • Integrated Quality Control: Each test cassette contains a unique barcode, enabling the i-ImmunDx™ Analyzer to automatically apply the correct calibration and protocol, ensuring test integrity and eliminating the need for manual updates when new tests are introduced.

Why Choose LTA-POC:

Traditional diagnostic methods for DED often lack specificity and fail to correlate with disease severity. The LTA-POC test addresses this gap by providing objective, molecular-level data on immune status, enabling clinicians to differentiate between DED subtypes and tailor interventions accordingly.

For more information, please contact us at sales@seindabio.com.

LTA-POC Brochure

Rapid Detection of Allergic Conjunctivitis

The IgE-POC is a point-of-care diagnostic test developed to measure total Immunoglobulin E (IgE) levels in tear fluid—offering a rapid, objective solution for the detection and assessment of allergic conjunctivitis.Designed for use with the i-ImmunDx™ Analyzer, this test enables clinicians to confirm allergy-related inflammation in minutes, improving diagnostic accuracy and supporting more targeted treatment decisions.

Clinical Value:

Allergic conjunctivitis can be difficult to distinguish from other forms of ocular surface inflammation based on symptoms alone. The IgE-POC test provides molecular-level confirmation, helping clinicians differentiate allergic from non-allergic causes of eye irritation and enabling more precise treatment planning—including appropriate use of antihistamines or anti-inflammatory therapies.

Key Features:

  • Fast Turnaround:
    Quantitative results available within 10–15 minutes at the point of care.
  • High Sensitivity:
    Accurately detects tear IgE levels, even at low concentrations, allowing for early identification of allergic responses.
  • Small Sample Volume:
    Requires only 1–2 µL of tear fluid, ensuring patient comfort and efficient workflow.
  • Barcode-Linked Protocol:
    Each cassette includes a unique barcode, allowing the analyzer to automatically select the correct test settings—no manual calibration or software updates required.

Why Choose IgE-POC:

  • Objective confirmation of allergy-related eye disease
  • Supports differential diagnosis in multifactorial dry eye or ocular discomfort
  • Simple, quick, and deployable in routine clinical practice

For more information, please contact us at sales@seindabio.com

IgE-POC Brochure

Inflammation Assessment for Dry Eye Disease

The MMP9-POC test is a quantitative point-of-care assay designed to detect Matrix Metalloproteinase-9 (MMP9) in tear fluid—a critical biomarker associated with ocular surface inflammation in Dry Eye Disease (DED).

Used with the i-ImmunDx™ Analyzer, the test provides clinicians with a rapid and objective tool to assess inflammatory status, improving diagnostic precision and treatment guidance.

Clinical Value:

MMP9 is an enzyme linked to the breakdown of corneal epithelial barrier function and inflammation in DED. Elevated levels are associated with more severe disease and poorer ocular surface health. The MMP9-POC test supports:

  • Differentiating inflammatory from non-inflammatory DED
  • Monitoring treatment response over time
  • Informing anti-inflammatory therapeutic decisions

Key Features:

  • Rapid Quantitative Results:
    Delivers actionable inflammation data in just 10-15 minutes at the point of care.
  • High Sensitivity & Precision:
    Detects subtle elevations in MMP9 that may not be evident through symptoms alone, enabling early and accurate intervention.
  • Low Sample Volume:
    Requires only 1-2 uL of tear fluid, minimizing discomfort and streamlining the workflow.
  • Barcode-lntegrated Protocol:
    Each cassette includes its own protocol barcode-automatically recognized by the i-ImmunDx™ Analyzer, ensuring accurate calibration without software updates.
  • Built-in Safety & Quality Checks:
    Each test run includes internal controls to verify result integrity and analyzer performance.

Why Choose MMP9-POC:

  • Provides real-time, objective inflammation status
  • Enhances DED subtyping and personalized care
  • Seamless integration into any eye care practice with minimal training

For more information, please contact us at sales@seindabio.com.

MMP9-POC Brochure

Launching in 2026

Launching in 2026

Linkedin